Heteroaromatic NMDA receptor modulators and uses thereof

US11542264B2 · kind B2 · utility

Assignee

• Cadent Therapeutics, Inc. · US

Inventors

• David R. Anderson · Salem, US
• Robert A. Volkmann · Mystic, US
• Gregg F. Keaney · Lexington, US
• Steven C. Leiser · Valley Cottage, US
• Sam Malekiani · Watertown, US
• Timothy Piser · Wilmington, US

Key dates

• Filing date: Feb 12, 2021
• Grant date: Jan 3, 2023
• Expiry date: Mar 5, 2041

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P25/28
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

Provided is 5-(3-chloro-4-fluorophenyl)-7-cyclopropyl-3-(2-(3-fluoro-3-methylazetidin-1-yl)-2-oxoethyl)-3,7-dihydro-4H-pyrrolo[2,3-d]pyrimidin-4-one and pharmaceutically acceptable salts thereof, and their uses in the treatment of psychiatric, neurological, and neurodevelopmental disorders, as well as diseases of the nervous system.